EBOS Group EPS up 17.5%
February 24, 2016
MAJOR healthcare equipment
and pharmacy products wholesaler
and distribution company EBOS
Group has announced strong
revenues from retail pharmacies in
Australia and New Zealand for the
six months to end Dec 2015.
Revenues touched $3.4b
representing 8.3% growth (9.0%
constant fx), giving profit before
tax of $91.7m, growth in earnings
per share of 17.5% and EBITDA up
13.3%.
The company declared an interim
dividend per share of 26 cents, up
18.2%.
The Group’s Animal Care sector
also contributed strongly to the
growth result and EBOS Group ceo
patrick Davies said the overall result
reflected the benefits of continued
organic growth and nearly $100m
in strategic investment across the
Group during the first half of last
year.
He added that the results
provided confidence for the Group
to continue investing in its key
markets to drive future growth and
improved returns for shareholders.
“Importantly we have been
able to fund our strategic
investments through either
cash flows generated by the
business or existing debt facilities,
thereby maximising our return on
investment,” he said.
The healthcare business brought
in EBITDA for the period of just
under $100m, up 12.7%, based on
revenue growth of 8.2%, said the
release.
EBOS Group acquired Red Seal, a
natural vitamins, supplements and
products business in November for
$80m and sees significant potential
for this part of the business to grow
the Endeavour Consumer Health
business in Australia, Davies said.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Feb 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Feb 16
